Conference Program

Tuesday, November 5

5:30 p.m.-8:00 p.m. Opening Remarks and Opening Keynote Session

Grand Ballroom

Session Chairperson: Cory Abate-Shen, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center,

New York, NY

Modeling pancreatic cancer biology and medicine

David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Developing therapeutics using the zebrafish

Leonard I. Zon, Children's Hospital Boston, Boston, MA

8:00 p.m.-9:30 p.m. Opening Reception

Palm Terrace

Wednesday, November 6

7:00 a.m.-8:00 a.m. Continental Breakfast

Palm Terrace

8:00 a.m.-10:00 a.m. Plenary Session 1: Translational Successes from Model

Organisms to the Clinic

Grand Ballroom

Session Chairperson: Pier Paolo Pandolfi, Beth Israel Deaconess

Medical Center, Boston, MA

8:00 a.m. The Co-Clinical Trial Project

Pier Paolo Pandolfi

8:30 a.m. **Modeling APL pathogenesis through therapy response**

Hugues de Thé, INSERM/CNRS, Paris, France

9:00 a.m. Using cross-species analysis of genome-wide regulatory networks

to identify drivers of cancer malignancy

Cory Abate-Shen, Columbia University Medical Center, Herbert Irving

Comprehensive Cancer Center, New York, NY

9:30 a.m. Paradoxical acceleration of pancreatic tumorigenesis through

Smoothened inhibition: A post-clinical trial in genetically engineered

mice*

Kenneth P. Olive, Columbia University Medical Center, Herbert Irving

Comprehensive Cancer Center, New York, NY

9:45 a.m. Targeting NOTCH1 and C-MYC in humanized models of relapsed and

induction failure pediatric T-ALL*

Michelle A. Kelliher, University of Massahusetts Medical School,

Worcester, MA

10:00 a.m.-10:30 a.m. Break

Grand Ballroom Foyer East

10:30 a.m12:30 բ	m. Plenary Session 2: Target Discovery and Validation Grand Ballroom Session Chairperson: A. Thomas Look, Dana-Far Cancer Institute, Boston, MA	ber:
10:30 a.m.	Mining the proteome of mouse models of cancer for diagnost and therapeutics Samir Hanash, The University of Texas MD Anderson Cancer Ce Houston, TX	
11:00 a.m.	Drosophila cancer models identify complex therapeutics Ross L. Cagan, Mount Sinai School of Medicine, New York, NY	
11:30 a.m.	BAP1: An emerging player in epigenetics and cancer* Anwesha Dey, Genentech Inc., South San Francisco, CA	
11:45 a.m.	A new class of drugs active in T-ALL is revealed in a zebrafis screen A. Thomas Look	sh
12:15 p.m.	Linking development and cancer modeling in zebrafish iden putative therapeutic targets in medullary thyroid cancer* Jacques A. Villefranc, Weill Cornell Medical College, New York, New Yo	

12:30 p.m.-2:30 p.m. Poster Session A with Lunch The Gallery

2:30 p.m.-4:30 p.m. Plenary Session 3: Mechanisms of Resistance

Grand Ballroom

Session Chairperson: Cory Abate-Shen, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York. NY

2:30 p.m. Studying therapy response and resistance in mouse models of

human breast cancer

Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands

3:00 p.m. Targeting the immune environment in humanized mice model of

breast cancer*

Te-Chia Wu, Baylor Institute for Immunology Research, Dallas, TX

3:15 p.m. Improving existing cancer therapy by targeting the tumor

microenvironment

Michael T. Hemann, David H. Koch Institute for Integrated Cancer

Research at MIT, Cambridge, MA

3:45 p.m. Clonal evolution enhances leukemia propagating cell activity in

T-cell acutelymphoblastic leukemia through AKT/mTORC1 pathway

activation*

Jessica Blackburn, Massachusetts General Hospital, Boston, MA

4:00 p.m. Understanding drug responses and resistance mechanisms using

imaging in live mice

Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

4:45 p.m.-6:45 p.m. Panel Discussion: Barriers and Next Steps: Effective

Preclinical Science for Cancer Patient Management

Grand Ballroom

Session Chairperson: Terry A. Van Dyke, National Cancer

Institute-Frederick, Frederick, MD

Confirmed Panelists:

Anton J. M. Berns, Netherlands Cancer Institute, Amsterdam, The Netherlands David Heimbrook, National Cancer Institute-Frederick/SAIC, Inc., Frederick, MD Leisa Johnson, Genentech, Inc., South San Francisco, CA Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Boston, MA Nancy K. Pryer, Novartis Institutes for BioMedical Research, Emeryville, CA David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY Terry A. Van Dyke

Thursday, November 7

7:00 a.m.-8:00 a.m. Continental Breakfast

Palm Terrace

8:00 a.m.-10:00 a.m. Plenary Session 4: Integrating Studies from Model

Organisms Using Genomic Approaches and Systems

Biology

Grand Ballroom

Session Chairperson: Andrea Califano, Columbia University, New

York, NY

8:00 a.m. The use of forward genetics for drug target discovery and the

identification of mediators of therapy resistance

David Adams, Wellcome Trust Sanger Institute, Cambridge, United

Kingdom

8:30 a.m. Interrogation of regulatory networks elucidates the genetic events

leading to the mesenchymal subtype of glioblastoma

Andrea Califano

9:00 a.m. Functional genomics and cancer vulnerabilities

William Hahn, Dana-Farber Cancer Institute, Boston, MA

9:30 a.m. The Ras genetic network in cancer progression in mouse models

Allan Balmain, UCSF Helen Diller Family Comprehensive Cancer Center,

San Francisco, CA

10:00 a.m.-10:30 a.m. Break

Grand Ballroom Foyer East

10:30 a.m12:30 p	Advances in Modeling Grand Ballroom Session Chairperson: Scott W. Lowe, Memorial Sloan-Kettering Cancer Center, New York, NY
10:30 a.m.	Accelerating translational research using ESC-GEMM models and inducible RNAi Scott W. Lowe
11:00 a.m.	RNAi mouse models: Revolutionizing drug discovery in vivo* Prem Premsrirut, Mirimus, Inc., Cold Spring Harbor, NY
11:15 a.m.	Identifying novel agents for treatment of childhood cancer: The PPTP experience Peter Houghton, Nationwide Children's Hospital, Columbus, OH
11:45 a.m.	Modeling human cancer therapeutic response: Evaluating the MAP kinase pathway in GEMMs, allografts, and patient-derived xenografts Nancy K. Pryer, Novartis Institutes for BioMedical Research, Emeryville, CA
12:15 p.m.	Man's best friend for cancer driver-passenger discrimination* Shaying Zhao, University of Georgia, Athens, GA

12:30 p.m.-2:30 p.m. Free Time/Lunch on Own

2:30 p.m4:30 p.m	Plenary Session 6: Translational Mechanisms of Initiation and Progression Grand Ballroom Session Chairperson: Timothy C. Wang, Columbia University Medical Center, New York, NY
2:30 p.m.	Pathogenesis of gastric cancer: Lessons and therapeutic targets from mouse models Timothy C. Wang
3:00 p.m.	Genetic interaction of NEDD9 with melanoma-prone oncogenes and tumor suppressor genes* Minjung Kim, Moffitt Cancer Center, Tampa, FL
3:15 p.m.	From melanocyte to melanoma: Identifying key molecular events at the onset of cancer* Charles K. Kaufman, Dana-Farber Cancer Institute, Boston, MA
3:30 p.m.	Canine cancer genetics: What dogs can tell us about ourselves Elaine A. Ostrander, NIH-NHGRI, Bethesda, MD
4:00 p.m.	Advanced Avatar models for studying cancer stem cell dynamics in human pancreatic ductal adenocarcinoma* Christopher Heeschen, Spanish National Cancer Research Centre (CNIO), Madrid, Madrid, Spain
4:15 p.m.	Directing personalized breast cancer treatment with pathway signatures* Eran R. Andrechek, Michigan State University, East Lansing, MI

4:30 p.m.-6:30 p.m. Poster Session B and Reception

The Gallery

Friday, November 8

7:00 a.m.-8:00 a.m. Continental Breakfast

Palm Terrace

8:00 a.m.-10:00 a.m. Plenary Session 7: Mechanisms of Cancer Progression

and Metastases: Opportunities for Translation

Grand Ballroom

Session Chairperson: Anton J. M. Berns, Netherlands Cancer

Institute, Amsterdam, The Netherlands

8:00 a.m. Tumor heterogeneity and cell-of-origin of mouse small cell and non-

small cell lung cancer

Anton J. M. Berns

8:30 a.m. Modeling recurrent metastatic melanoma in the mouse

Glenn T. Merlino, National Cancer Institute, Bethesda, MD

9:00 a.m. Using mouse models to identify and target key chromatin regulators

in cancer

Karen Cichowski, Brigham and Women's Hospital, Boston, MA

9:30 a.m. Using a hypoxia-induced CSC tumor initiation model to improve

predictive potential for patients with metastatic breast cancer*
Emily Chen, Columbia University Medical Center, Herbert Irving

Comprehensive Cancer Center, New York, NY

9:45 a.m. Quantitative and multiparameter analysis of tumor cell intravasation*

Elena I. Deryugina, The Scripps Research Institute, La Jolla, CA

10:00 a.m.-10:30 a.m. Break

Grand Ballroom Foyer East

10:30 a.m.-12:30 p.m. Plenary Session 8: Advances in Preclinical Studies

Grand Ballroom

Session Chairperson: Terry A. Van Dyke, National Cancer

Institute-Frederick, Frederick, MD

10:30 a.m. Genetic and preclinical evaluation of genetically engineered mouse

models of lung cancer

Leisa Johnson, Genentech, Inc., South San Francisco, CA

11:00 a.m. Therapeutic evaluation in genetically engineered cancer models

Terry A. Van Dyke

11:30 a.m. Title to be announced

Kwok-Kin Wong, Dana-Farber Cancer Institute, Boston, MA

12:00 p.m. Insights into acquired resistance to targeted therapies from mouse

models of lung cancer

Katerina A. Politi, Yale Cancer Center, New Haven, CT

12:30 p.m. Departure



UPCOMING CONFERENCES

Sixth Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

Co-Chairpersons: John D. Carpten, Christopher I. Li, and Olufunmilayo I. Olopade December 6-9, 2013 Atlanta, GA

CTRC-AACR San Antonio Breast Cancer Symposium

Co-Directors: Carlos L. Arteaga, C. Kent Osborne, and Peter M. Ravdin December 10-14, 2013 San Antonio, TX

AACR-IASLC Joint Conference on the Molecular Origins of Lung Cancer

Co-Chairpersons: Roy Herbst, Elisabeth Brambilla, Pasi Jänne, and William Pao January 6-9, 2014 San Diego, CA

AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research

Co-Chairpersons: Arul M. Chinnaiyan, William G. Nelson, June M. Chan, and Jonathan W. Simons January 18-21, 2014 San Diego, CA

Cancer Susceptibility and Cancer Susceptibility Syndromes

Co-Chairpersons: Alan D. D'Andrea, Phillip A. Dennis, and Pier Paolo Pandolfi January 29-February 1, 2014 San Diego, CA

RAS Oncogenes: From Biology to Therapy

Co-Chairpersons: Dafna Bar-Sagi, Channing J. Der, and Frank McCormick February 24-27, 2014 Lake Buena Vista, FL

Cellular Heterogeneity in the Tumor Microenvironment

Co-Chairpersons: Mary Helen Barcellos-Hoff, Michele De Palma, and M. Celeste Simon February 26-March 1, 2014 San Diego, CA

AACR Annual Meeting 2014

Program Committee Chairperson: Scott W. Lowe April 5-9, 2014 San Diego, CA

Pancreatic Cancer

Co-Chairpersons: Dafna Bar-Sagi, David A. Tuveson, Christine Iacobuzio-Donahue, and Alec Kimmelman May 18-21, 2014 New Orleans, LA

AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy

Co-Chairpersons: Gideon Bollag, Elaine Mardis, Gordon Mills, and David Solit June 18-21, 2014 Orlando, FL

Targeting the PI3K-mTOR Network in Cancer

Co-Chairpersons: Lewis C. Cantley, Jose Baselga, Joan S. Brugge, Brendan J. Manning, and Malte Peters September 14-17, 2014 Philadelphia, PA

Hematological Malignancies

Co-Chairpersons: Kenneth C. Anderson, Scott Armstrong, Riccardo Dalla-Favera, and Margaret Shipp September 20-23, 2014 Philadelphia, PA

Melanoma

Co-Chairpersons: Levi A.
Garraway, Keith T. Flaherty, and
Suzanne L. Topalian
September 20-23, 2014
Philadelphia, PA

13th Annual International Conference on Frontiers in Cancer Prevention Research

Program Committee Chairperson: Phillip A. Dennis September 28-October 1, 2014 New Orleans, LA

EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics

Scientific Committee Co-Chairpersons: Jean-Charles Soria, Lee J. Helman, and Jeffrey A. Engelman November 18-21, 2014 Barcelona, Spain

Tumor Immunology

Co-Chairpersons: Robert H. Vonderheide, Nina Bhardwaj, Stanley Riddell, and Cynthia L. Sears December 1-4, 2014 Orlando, FL

Please visit

www.aacr.org/
meetingcalendar
for additional conferences and
program updates.